Sutro Biopharma (STRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Jane Chung, Connie Matsui, and James Panek, with board recommending a vote for all nominees.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory vote to approve compensation of named executive officers, with board recommending approval.
Board of directors and corporate governance
Board is seeking shareholder approval for the election of three Class II directors at the 2026 annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, allowing shareholders to express approval or disapproval of named executive officer pay.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sutro Biopharma
- Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.STRO
Proxy filing23 Apr 2026 - Next-gen ADCs advance with robust pipeline, dual-payload innovation, and strong clinical progress.STRO
Corporate presentation23 Apr 2026 - Next-generation ADCs advance toward key milestones, targeting major oncology markets with strong data.STRO
Corporate presentation24 Mar 2026 - Up to $300M in securities registered, including $100M ATM equity via TD Cowen for broad corporate use.STRO
Registration filing23 Mar 2026 - Revenue up 65% to $102.5M, net loss narrowed, and cash runway extended into 2028.STRO
Q4 202523 Mar 2026 - Accelerated ADC pipeline advances with key clinical data and INDs expected in the next year.STRO
The Citizens Life Sciences Conference 202610 Mar 2026 - Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year.STRO
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Accelerated ADC pipeline and platform innovation drive clinical progress and strategic growth.STRO
44th Annual J.P. Morgan Healthcare Conference3 Feb 2026 - Luvelta's pivotal trials and platform innovation target broader patient access and industry leadership.STRO
2024 Wells Fargo Healthcare Conference22 Jan 2026